Abbott Laboratories $ABT Shares Purchased by Schroder Investment Management Group

Schroder Investment Management Group grew its stake in shares of Abbott Laboratories (NYSE:ABT) by 10.3% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,256,689 shares of the healthcare product maker’s stock after buying an additional 117,386 shares during the period. Schroder Investment Management Group owned 0.07% of Abbott Laboratories worth $168,321,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in ABT. Cloud Capital Management LLC acquired a new stake in shares of Abbott Laboratories during the third quarter valued at $29,000. Guerra Advisors Inc purchased a new position in Abbott Laboratories in the 3rd quarter valued at about $31,000. Anfield Capital Management LLC boosted its stake in shares of Abbott Laboratories by 81.3% during the 2nd quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock worth $32,000 after purchasing an additional 104 shares during the last quarter. Delos Wealth Advisors LLC purchased a new stake in shares of Abbott Laboratories during the second quarter worth about $32,000. Finally, Bridge Generations Wealth Management LLC acquired a new position in shares of Abbott Laboratories in the third quarter valued at approximately $33,000. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Abbott Laboratories

In related news, EVP Elizabeth C. Cushman sold 263 shares of the stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $30,397.54. Following the completion of the sale, the executive vice president owned 38,573 shares of the company’s stock, valued at approximately $4,458,267.34. This represents a 0.68% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Mary K. Moreland sold 613 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $70,850.54. Following the completion of the transaction, the executive vice president owned 104,291 shares in the company, valued at $12,053,953.78. The trade was a 0.58% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 3,055 shares of company stock worth $353,097. Company insiders own 0.46% of the company’s stock.

Abbott Laboratories Stock Up 2.9%

Shares of ABT opened at $112.69 on Tuesday. Abbott Laboratories has a fifty-two week low of $105.27 and a fifty-two week high of $139.15. The company’s fifty day moving average is $115.86 and its two-hundred day moving average is $124.44. The firm has a market cap of $195.82 billion, a PE ratio of 30.29, a price-to-earnings-growth ratio of 1.74 and a beta of 0.74. The company has a quick ratio of 1.18, a current ratio of 1.58 and a debt-to-equity ratio of 0.19.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, hitting analysts’ consensus estimates of $1.50. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The business had revenue of $11.46 billion during the quarter, compared to the consensus estimate of $11.80 billion. During the same period in the prior year, the firm posted $1.34 EPS. The business’s revenue for the quarter was up 4.4% on a year-over-year basis. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Analysts forecast that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be paid a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 2.2%. The ex-dividend date of this dividend is Wednesday, April 15th. Abbott Laboratories’s payout ratio is currently 67.74%.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the stock. Argus decreased their target price on shares of Abbott Laboratories from $150.00 to $140.00 in a research report on Tuesday, January 27th. Freedom Capital raised Abbott Laboratories from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 29th. Evercore decreased their price objective on Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Daiwa Securities Group dropped their target price on Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating for the company in a research note on Friday, January 30th. Finally, Citigroup reduced their target price on Abbott Laboratories from $155.00 to $140.00 and set a “buy” rating on the stock in a research report on Friday, January 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $136.37.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.